The Hewitt Centre at Liverpool Women’s NHS Foundation Trust UK has installed the Auxogyn early embryo viability assessment (Eeva) test.

"Eeva’s quantitative data for each embryo’s potential development will allow IVF clinics to optimise the treatment path for patients."

The Eeva test is designed to improve IVF outcomes by assessing embryo viability and providing clinicians and patients with objective information.

The computer vision software is used in Eeva to measure key scientifically and clinically validated cell-division parameters from video images, and predicts the embryo at the cleavage stage which is likely to grow to the blastocyst stage.

Charles Kingsland, Liverpool Women’s NHS Foundation Trust Hewitt Centre lead consultant and consultant gynaecologist, said Eeva gives patients the best chance of a successful embryo implantation.

"At the Hewitt Fertility Centre, we are committed to doing everything we can, including adopting breakthrough technologies, to improve embryo selection in order to increase a patient’s success of pregnancy while reducing the risks associated with multiple births," Kingsland added.

"By using Eeva, we will be able to help our patients make more informed personal decisions and provide them with the best care possible."

The Eeva’s quantitative data for each embryo’s potential development will allow IVF clinics to optimise the treatment path for patients undergoing IVF procedures, according to Auxogyn.

In a prospective, multicentre, 160-patient clinical trial, Eeva was able to predict blastocyst formation at the cleavage stage with 85% specificity, reducing the false positive rate from 43% to 15% compared with traditional morphology selection.

Eeva demonstrated its ability to track and analyse cell division timings with more than a 90% accuracy and could increase the consistency of embryo assessment across embryologists.

Lissa Goldenstein, Auxogyn president and chief executive officer, said: "With the commercial launch of Eeva, IVF clinics and their patients will now have access to the first and only noninvasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential for transfer."